On Friday, Johnson & Johnson Inc. said that its developing coronavirus vaccine has a 72% efficacy rate in U.S. trials, a lower-than-expected result. It had an overall/global efficacy rate of 66% in the 44,000 person study of patients with moderate to severe forms of COVID-19.
J&J’s one-shot vaccine doesn't require excessively low temperatures to store. The trial also revealed an 85% rate of protection against patients with more severe forms. It showed a 57% rate of efficacy against the new strain of the virus recently identified in South Africa.
The company said it would apply for Emergency Use Authorization from the U.S. Food & Drug Administration as early as next week.